Skip to main content
Premium Trial:

Request an Annual Quote

Prenatal Testing Startup Juno Diagnostics Closes $25M Series A Financing Round

NEW YORK – Prenatal genetic testing firm Juno Diagnostics said on Wednesday that it has closed an expanded $25 million Series A financing round.

The round was led by the Perceptive Xontogeny Venture Fund. The company said the funding will be used to support clinical validation studies, product development, and commercialization. Juno said in a statement that it generated "a differentiated product offering" and a "collection of promising clinical data" to support the round.

San Diego-based Juno Diagnostics is developing a noninvasive prenatal test using cell-free DNA that "simplifies sample collection and improves access to high-quality genetic testing results without the high cost, long lead times, and phlebotomy requirements of traditional NIPT," the firm added.

"With a highly experienced and motivated team, JunoDx is positioned to become the cfDNA testing market leader driven by a sea change in reimbursement and democratizing access via technology innovation," said Chris Garabedian, CEO of Xontogeny and manager of the PXV Fund for Perceptive Advisors.

The company's founders previously worked on developing NIPT at Sequenom.

The Scan

Taking Stock of the Stockpile

The US and European countries are evaluating their smallpox vaccine stockpiles as the number of monkeypox cases increases, the Washington Post reports.

Vitamin D From Tomatoes

According to Reuters, researchers in the UK have gene-edited tomatoes so their fruit contains vitamin D.

Cause Not Yet Spotted

NPR reports that a new study was unable to find a cause for persistent long COVID symptoms.

PNAS Papers on Central African Hunter-Gatherers, Myopia Development, Ancient Microtia Allele

In PNAS this week: population patterns among Central African hunter gatherers, effect of myopia-linked gene variant, and more.